|Chemical and physical data|
|Molar mass||489.08 g·mol−1|
|3D model (JSmol)|
BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia, it's an ester of GABA and perphenazine, and pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials. In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|